MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

CureVac NV

Closed

5.39

Overview

Share price change

24h

Current

Min

5.39

Max

5.4

Key metrics

By Trading Economics

Income

-8.3M

-60M

Sales

352K

1.2M

P/E

Sector Avg

5.297

35.739

Profit margin

-4,816.546

Employees

825

EBITDA

-8.2M

-55M

Dividends

By Dow Jones

Next Earnings

11 lis 2025

Market Stats

By TradingEconomics

Market Cap

-18M

1.2B

Previous open

5.39

Previous close

5.39

Technical Score

By Trading Central

Confidence

Bullish Evidence

CureVac NV Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 cze 2025, 14:20 UTC

Acquisitions, Mergers, Takeovers

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 cze 2025, 13:34 UTC

Hot Stocks

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

Peer Comparison

Price change

CureVac NV Forecast

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

3.47 / 3.755Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
help-icon Live chat